Natera, Inc. ($NTRA) Stock Forecast: Up 5.9% Today

What is Natera, Inc.?

Natera Inc (NTRA) is a company specializing in genetic testing technologies, with a recent focus on cancer diagnostics and IVF genetic testing. Today, the stock experienced a strong bullish movement in the market.

Why is Natera, Inc. going up?

NTRA stock is up 5.9% on Jun 23, 2026 14:16

• The bullish movement in NTRA stock today can be attributed to the positive news of NCCN updating its bladder cancer guidelines to recommend ctDNA-MRD testing using Signatera™ technology, a significant development that validates Natera's technology and is expected to drive adoption in oncology practices.
• Despite the positive news, there was a slight dip in the stock price (-1.13%) following a Form 4 filing and insider selling activity by a co-founder's family trusts. This could have caused some initial uncertainty among investors, leading to the minor decrease in stock value.
• The class action lawsuit against Natera regarding IVF genetic testing claims could have added some pressure on the stock, but the overall market sentiment seems to have been more influenced by the positive NCCN guideline update, overshadowing the legal challenges the company is facing.
• Investors should keep an eye on how Natera addresses the profitability challenges and maintains market confidence amidst legal disputes, while also capitalizing on the momentum gained from the NCCN endorsement for its Signatera technology.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

The National Comprehensive Cancer Network (NCCN) has updated its bladder cancer guidelines to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing using Signatera™ technology for patients with muscle-invasive bladder cancer (MIBC). This marks a significant development, as it allows for risk stratification and guides the use of adjuvant immunotherapy post-cystectomy, earning a Category 1 recommendation for Signatera-guided treatment. The update is based on strong evidentiary support, including the landmark IMvigor011 trial, and is expected to influence broader MRD-guided cancer care.

https://www.businesswire.com/news/home/20260623843077/en/NCCN-Recommends-ctDNA-MRD-Testing-Using-Signatera-Technology-in-Landmark-Bladder-Cancer-Guideline-Update

Form 4 Natera Inc For: 22 June By Investing.com

This Investing.com article reports on a Form 4 filing for Natera Inc (NTRA) on June 22. It briefly mentions the company's stock performance (-1.13%) and provides a basic headline without further details on the filing's content. The rest of the page consists of general financial news headlines, market data, and promotional content from Investing.com.

https://ca.investing.com/news/stock-market-news/form-4-natera-inc-for-22-june-93CH-4702305

Natera (NTRA) co-founder’s family trusts sell 1,500 shares under 10b5-1 plan

Family trusts associated with Sheena Jonathan, a co-founder and director of Natera (NTRA), sold 1,500 shares of company stock on June 17, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales occurred through open-market transactions at weighted average prices in the low- to mid-$220 per share range. Following these transactions, Jonathan and the trusts continue to hold significant shares in Natera.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-1362574a745a.html

Signatera (NTRA) Gains Momentum with New NCCN Bladder Cancer Guidelines

Natera's Signatera has gained significant momentum with its inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for bladder cancer, endorsing minimal residual disease (MRD) testing. This validation is expected to drive adoption in oncology practices and enhance the company's market presence. Despite strong growth potential and a solid balance sheet, investors should note the company's challenges in profitability and recent insider selling activity.

https://www.gurufocus.com/news/8925482/signatera-ntra-gains-momentum-with-new-nccn-bladder-cancer-guidelines

Natera IVF Genetic Testing Class Action Lawsuit Claims PGT-A Results Were Misleading

A new class action lawsuit has been filed against Natera, alleging that the company falsely marketed its preimplantation genetic testing for aneuploidy (PGT-A) as 99% accurate and effective for improving IVF outcomes. The lawsuit claims that this misleading marketing led prospective parents to discard potentially viable embryos, resulting in significant financial and emotional costs without proven clinical benefits. The plaintiffs emphasize that scientific evidence does not support Natera's claims of increased pregnancy or live birth rates, and major insurers often classify PGT-A as unproven.

https://www.aboutlawsuits.com/natera-ivf-genetic-testing-class-action-lawsuit-pgt-a-results-misleading/

Trending Today

Corning Incorporated ($GLW) Stock Forecast: Down 5.2% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 8.0% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 6.0% Today

Taiwan Semiconductor Manufacturing Company Ltd. ($TSM) Stock Forecast: Down 5.5% Today

Invesco Ltd ($IVZ) Stock Forecast: Down 5.2% Today

International Business Machines Corporation ($IBM) Stock Forecast: Up 8.4% Today

Micron Technology Inc. ($MU) Stock Forecast: Down 8.9% Today

Qualys Inc. ($QLYS) Stock Forecast: Up 5.2% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 5.5% Today

Freeport-McMoRan Inc. ($FCX) Stock Forecast: Down 6.0% Today

Natera, Inc. Price History

08.04.2026 - NTRA Stock was down 7.7%

• Despite strong revenue growth driven by successful products like Fetal Focus and Signatera MRD test, Natera faced a bearish movement in its stock, potentially linked to a wider net loss reported in the same quarter, raising concerns about profitability.
• The missed EPS estimate and increased operating expenses leading to a higher net loss are likely factors contributing to the negative market sentiment towards Natera.
• Investors may be concentrating on the company's ability to manage expenses and bottom line performance, somewhat overshadowing the positive revenue growth and raised revenue guidance for the full year.
• The market's response could also be influenced by the stock's recent underperformance compared to the broader market, despite surpassing revenue expectations, suggesting a possible mismatch in investor expectations and market valuation.

23.05.2026 - NTRA Stock was up 5.9%

• The bullish movement in NTRA stock today can be attributed to the positive news of NCCN updating its bladder cancer guidelines to recommend ctDNA-MRD testing using Signatera™ technology, a significant development that validates Natera's technology and is expected to drive adoption in oncology practices.
• Despite the positive news, there was a slight dip in the stock price (-1.13%) following a Form 4 filing and insider selling activity by a co-founder's family trusts. This could have caused some initial uncertainty among investors, leading to the minor decrease in stock value.
• The class action lawsuit against Natera regarding IVF genetic testing claims could have added some pressure on the stock, but the overall market sentiment seems to have been more influenced by the positive NCCN guideline update, overshadowing the legal challenges the company is facing.
• Investors should keep an eye on how Natera addresses the profitability challenges and maintains market confidence amidst legal disputes, while also capitalizing on the momentum gained from the NCCN endorsement for its Signatera technology.

15.04.2026 - NTRA Stock was down 5.3%

• Natera's stock experienced a strong bearish movement of 5.9% today.
• The market reacted negatively to Natera's Q1 2026 earnings report despite raising its 2026 revenue and gross margin guidance. This can be attributed to the wider net loss of US$85.09 million due to increased operating expenses for clinical trials, new products, and international expansion.
• Cathie Wood's ARK Invest's strategic shift towards increasing its stake in Natera while selling shares in other biotech companies may have also influenced market sentiment, signaling a shift in focus within the biotech sector.
• Analysts' mixed reactions to Natera's first-quarter results, with revenue beating expectations but statutory losses being larger than forecast, could have added to the overall bearish sentiment surrounding the stock.

20.04.2026 - NTRA Stock was up 5.1%

• The FDA's approval of Natera's Signatera CDx blood test as a companion diagnostic for muscle-invasive bladder cancer has led to a surge in the company's stock performance.
• This approval underscores the importance of MRD testing as a critical tool in clinical decision-making, potentially boosting revenue projections for Natera.
• Despite these positive developments, investors are advised to be wary of Natera's high expenditures, ongoing financial losses, as well as legal and regulatory challenges that could affect its future growth prospects.
• Despite recent declines in the stock price, Natera's robust revenue growth and optimistic analyst outlook suggest that the company may be undervalued, offering investors an opportunity to consider a bullish stance on Natera for the long term.

29.04.2026 - NTRA Stock was up 7.1%

• The bullish movement in Natera's stock could be attributed to the positive market reception of its collaboration with Diakonos Oncology Corp. for a Phase I/II trial in refractory melanoma using the Signatera test. This partnership aims to provide early insights into treatment response dynamics, which is a significant development in the field of personalized medicine.
• The recent sale of shares by the company's executives to cover tax obligations may have initially caused some uncertainty among investors. However, the market seems to have focused more on the promising collaboration and the potential impact on cancer treatment.
• Natera's announcement of an enhanced Panorama non-invasive prenatal test (NIPT) could also have contributed to the positive sentiment, showcasing the company's continued efforts in advancing its genetic testing portfolio and addressing medical needs across different areas.
• Overall, the market's bullish reaction to Natera's strategic collaborations and product enhancements reflects investor confidence in the company's growth prospects and its commitment to driving innovation in genetic testing and personalized medicine.

04.05.2026 - NTRA Stock was up 5.4%

• The bullish movement in Natera's stock today can be attributed to the positive news of the company expanding its board of directors with oncology experts, Thomas Lynch and Eric Rubin. This move is seen as strengthening the company's capabilities in a sector where it has experienced significant growth.
• Additionally, the announcement of Natera expanding its operations in Austin with a new sequencing facility, expected to create 200 new jobs, likely boosted investor confidence in the company's future prospects and growth potential.
• The upgrade of Natera's rating to "Outperform" by Wolfe Research, despite concerns about insider selling, also contributed to the bullish sentiment surrounding the stock. The price target of $260.00 reflects a positive outlook on Natera's performance in the medical diagnostics industry.

04.05.2026 - NTRA Stock was up 5.0%

• The collaboration with CytoDyn in the colorectal cancer study has generated positive investor sentiment towards Natera's expertise in oncology, resulting in a bullish uptrend in the stock.
• The inclusion of oncology specialists on Natera's board of directors strengthens the company’s market position and enhances its standing in the realm of personalized medicine.
• Disclosures of a director receiving $425K in RSU equity and the president of clinical diagnostics selling shares have had a marginal effect on stock movement, but the enthusiasm surrounding the strategic collaboration outweighs these transactions.
• Natera's focus on utilizing molecular insights and real-world data to optimize treatment responses in colorectal cancer and other solid tumors underscores its dedication to advancing precision medicine and fostering growth in the oncology sector.

06.04.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera's stock today is linked to positive developments such as an "Outperform" rating from William Blair, a patent victory, and promising study results for its Signatera assay.
• The selling of shares by key executives like Sheena Jonathan, John Fesko, and CEO Steven Chapman to cover tax obligations initially raised concerns. However, these pre-arranged transactions, in light of positive news, likely reassured investors about the company's health and future prospects.
• Strategic selling of shares by company insiders under Rule 10b5-1 plans, despite the stock being down year-to-date, may indicate a prudent approach to finance management while maintaining confidence in company performance.
• The combination of positive company developments and strategic insider selling likely fueled the bullish movement in Natera's stock today, demonstrating a blend of financial responsibility and investor confidence in the company's growth trajectory.

28.04.2026 - NTRA Stock was up 5.1%

• Today's bullish movement in Natera's stock is likely linked to positive updates on its clinical trials and innovations in genetic testing technologies.
• Commencement of patient enrollment for early-stage breast cancer studies and progress in trials for breast cancer and bladder cancer treatments have contributed to increased investor confidence.
• Upgrades to the Panorama prenatal test and FDA approval for Signatera in bladder cancer demonstrate Natera's dedication to innovation and expanding its market reach.
• Despite concerns regarding insider selling and valuation risks, the favorable outcomes in Natera's clinical trials and testing capabilities appear to have had a stronger impact, resulting in an upsurge in the stock price.

02.05.2026 - NTRA Stock was down 5.3%

• The bearish movement in NTRA today could be attributed to the significant insider selling totaling $56.0 million in the last three months, raising concerns among investors about the company's future prospects.
• Despite an optimistic "Outperform" rating and a price target of $260.00, the overvaluation of Natera by 9.2% according to GF Value™ might have contributed to the downward pressure on the stock.
• The rejection of an appeal in the false-advertising dispute with Natera by the U.S. Supreme Court could have added uncertainty and legal risks to Natera's operations, impacting investor confidence in the stock.
• While Natera has announced positive developments such as enhanced prenatal testing and market expansion, the ongoing insider selling and legal disputes might have overshadowed these advancements, leading to the bearish market movement today.

08.04.2026 - NTRA Stock was down 6.0%

• Natera's strong revenue growth and milestone of processing over 1 million tests in a quarter showcased its continued expansion and market demand for its services.
• The wider loss per share than expected could have contributed to the bearish movement in the stock, despite positive revenue performance.
• The sale of shares by the Executive Chairman to cover tax obligations may have also impacted investor sentiment, leading to a decline in the stock price.
• Overall, while Natera's operational performance remains robust, market reaction to the earnings miss and insider selling likely drove the bearish movement in the stock today.

11.04.2026 - NTRA Stock was up 5.1%

• Despite concerns over its high valuation influencing a decline in stock price, Natera's impressive Q1 earnings call, demonstrating revenue growth and increased volume, has boosted investor confidence.
• Analysts have raised the 12-month price target to $260.78, indicating a 19% potential upside, reflecting optimism regarding Natera's future performance.
• The unexpected Q4 profit of US$47.3 million has shifted focus from prior losses to potential growth, although discussions on the stock's valuation persist among investors.
• Analysts' continued Buy rating and optimistic outlook, with target prices spanning from $136 to $285, further bolster the positive trajectory of Natera's stock.